(IN BRIEF) Sanofi and Orano Med have partnered to accelerate the development of next-generation radioligand therapies (RLTs) for rare cancers. By combining their expertise, they aim to advance treatments using lead-212 (212Pb) alpha-emitting isotopes, which target and destroy cancer cells … Read the full press release →
Posted in Business, Environment, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Cancer Therapies, Nicolas Maes, Orano Med, partnership, Paul Hudson, radioligand therapies (RLTs), rare cancers, safety, Sanofi, sustainability, USA